TET enzymes are iron- and α-ketoglutarate-dependent dioxygenases that initiate DNA demethylation by oxidizing 5-methylcytosine through a series of intermediates—5-hydroxymethylcytosine, 5-formylcytosine, and 5-carboxylcytosine—that are ultimately returned to unmodified cytosine by thymine DNA glycosylase and base-excision repair. First identified as a fusion partner in leukemia and later shown to generate the "sixth base" 5hmC, the TET family (TET1, TET2, TET3) now sits at the center of epigenetic regulation in development, differentiation, and disease. This guide explains how TET proteins recognize and oxidize methylated DNA, the two routes by which demethylation is completed, why loss of TET2 is one of the most frequent events in myeloid malignancies, how metabolic intermediates such as 2-hydroxyglutarate and ascorbate tune TET activity, and the growing role of TET and 5hmC in immunity and as biomarkers. To support epigenetics research, we provide TET1 detection reagents, nucleic-acid methylation antibody panels, DNA methylation analysis services, and a broad epigenetics antibody catalog.
Molecular Mechanism
TET proteins are Fe(II)- and α-ketoglutarate (α-KG)-dependent dioxygenases. In a reaction that consumes α-KG and molecular oxygen and releases succinate and carbon dioxide, the catalytic domain hydroxylates the methyl group of 5mC at the 5 position, yielding 5hmC. The enzymes do not stop there: TETs can continue oxidizing 5hmC to 5fC and then to 5caC, so the true substrate spectrum comprises the three oxidized derivatives of 5mC. These oxidized forms are sometimes described as the "sixth, seventh, and eighth bases" of the genome because, unlike 5mC, they are not simply a silent mark but intermediates on the way to erasure.
Structural and biochemical work shows that the TET catalytic domain grips a flipped-out cytosine and positions its methyl group for oxidation, while the CXXC domain in TET1 and TET3 tethers the enzyme to CpG islands. Catalytic efficiency depends on local sequence context, CpG density, and the availability of metabolic co-substrates. Crucially, α-KG is required, and its competitors—cellular succinate or the oncometabolite 2-hydroxyglutarate—can block activity, creating a direct metabolic link between cellular state and demethylation. This sensitivity is not a curiosity; it is the mechanistic bridge between metabolism and epigenetic control.
Figure 1. TET enzymes and DNA demethylation. (Source: Bakrim S, et al. 2025)
Pathways of DNA Demethylation
Oxidation by TET does not itself erase the mark; it creates intermediates that are resolved by two routes. In active demethylation, 5fC and 5caC are recognized and excised by thymine DNA glycosylase, which triggers base-excision repair that replaces them with unmodified cytosine. This route can remove methylation independently of replication and is especially important in non-dividing cells and during developmental reprogramming, where a mark must be lifted without waiting for cell division.
In passive demethylation, 5hmC and the other oxidized forms are poor substrates for the maintenance methyltransferase DNMT1 and its cofactor, so when a cell divides the mark is not faithfully copied to the daughter strand and is diluted over successive rounds of replication. The combination of TET oxidation plus replication-dependent dilution progressively lowers methylation without explicit base excision. The two routes cooperate, and their relative contribution varies by tissue and developmental stage—active demethylation dominates where rapid, replication-independent resetting is needed, while passive dilution shapes marks in proliferating populations.
TET2 and Human Disease
Somatic mutations in TET2 are among the most frequent alterations in myeloid malignancies, including myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Most are loss-of-function changes that truncate or destabilize the protein, lowering 5hmC levels and impairing demethylation at key regulatory regions. TET2 loss enhances the self-renewal of hematopoietic stem cells and cooperates with other lesions to drive transformation, which helps explain why it appears so early and so often in these diseases.
The disease reach of TET2 extends beyond classic hematologic malignancy. TET2 mutations also arise in age-related clonal hematopoiesis, where they give blood stem cells a competitive advantage and are independently associated with increased risk of atherosclerotic cardiovascular disease. Because TET2 mutations and the metabolic inhibition of TET2 converge on the same failure of demethylation, they are typically mutually exclusive with mutations in the metabolic enzymes IDH1 and IDH2. This genetic logic—block the pathway by mutation or by metabolism, but rarely both—is a recurring theme in myeloid disease and a useful clue for interpreting coexisting alterations.
Metabolism, IDH, and Vitamin C
TET activity is exquisitely sensitive to cellular metabolism because α-KG is a required co-substrate and its analogs are inhibitors. Gain-of-function mutations in IDH1 and IDH2—common in glioma, cholangiocarcinoma, and subsets of AML—redirect the enzyme to produce the oncometabolite (R)-2-hydroxyglutarate (2-HG). 2-HG competes with α-KG at the TET active site, suppresses oxidation of 5mC, and produces a genome-wide hypermethylation phenotype that blocks differentiation. Notably, IDH and TET2 mutations are mutually exclusive, consistent with their acting in the same pathway and underscoring metabolism as a direct regulator of the epigenome.
Ascorbate (vitamin C) is a physiological cofactor that can enhance TET dioxygenase activity, and its depletion reduces 5hmC in several contexts. In leukemia models, restoring ascorbate or TET2 function promotes demethylation, curbs aberrant self-renewal, and slows disease progression, pointing to a metabolic route to reinforce TET activity therapeutically. These findings reframe TET not merely as a DNA-modifying enzyme but as a metabolic sensor whose output is tuned by the nutrient and energetic state of the cell—a perspective that links diet, metabolism, and epigenetic aging.
Figure 2. Inhibition of TET mediated DNA demethylation processes by mutant IDH1/2. (Source: Nakajima H, et al. 2014)
Immune Function and Therapeutic Prospects
TET enzymes shape the immune system at multiple levels. In T lymphocytes, TET2-mediated demethylation is required for the specification and function of T helper 17 cells, a subset implicated in autoimmunity and host defense, by opening key cytokine loci. In innate immunity, TET proteins influence macrophage activation and inflammasome regulation, and 5hmC dynamics track with immune cell differentiation and response. The breadth of these effects positions TET as a node linking metabolism, epigenetics, and immune output rather than a narrowly developmental enzyme.
Therapeutically, several strategies engage the TET pathway. Inhibitors of mutant IDH that lower 2-HG can indirectly restore TET activity; agents that modulate α-KG metabolism are being explored to shift epigenetic state; and vitamin C is under investigation as an adjunct to differentiation-based therapies in TET2- or IDH-mutant leukemia. Beyond therapy, 5hmC mapping and TET-targeted sequencing have emerged as research tools and potential diagnostic applications for charting active demethylation and for stratifying tumors by their epigenetic state. As detection becomes more quantitative, 5hmC is moving from a curiosity to a practical biomarker.
Frequently Asked Questions
TET2 is a tumor suppressor in the hematopoietic system. Loss-of-function mutations reduce 5hmC, impair demethylation at regulatory regions, and increase the self-renewal of blood stem cells, cooperating with other lesions to drive myeloid transformation. They are among the most frequent alterations in myelodysplastic syndromes and acute myeloid leukemia.
Gain-of-function IDH mutations produce the oncometabolite 2-hydroxyglutarate, which competes with α-ketoglutarate at the TET active site and inhibits oxidation of 5mC. This creates a hypermethylation phenotype that blocks differentiation. Because IDH and TET2 lesions act in the same pathway, they are typically mutually exclusive in tumors.
Yes. Ascorbate is a physiological cofactor that can enhance TET dioxygenase activity. In leukemia models, restoring ascorbate or TET2 function promotes demethylation and reduces aberrant self-renewal, supporting exploration of vitamin C as an adjunct to differentiation-based therapies.
5hmC is a dynamic mark of active demethylation whose distribution changes in development, aging, and disease. Quantitative mapping of 5hmC and related oxidized bases is increasingly used in research to chart epigenetic state, and it is being evaluated as a biomarker for tumor stratification and other applications.
References
- Bakrim S, et al. Epi-nutrients for cancer prevention: Molecular mechanisms and emerging insights. Cell Biol Toxicol. 2025 Jul 15;41(1):116.
- Nakajima H, et al. TET2 as an epigenetic master regulator for normal and malignant hematopoiesis. Cancer Sci. 2014 Sep;105(9):1093-9.
- Tahiliani M, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009 May 15;324(5929):930-5.
- Ito S, et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 2010 Aug 26;466(7310):1129-33.
- Figueroa ME, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010 Dec 14;18(6):553-67.
- Cimmino L, et al. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. Cell. 2017 Sep 7;170(6):1079-1095.e20.